Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals, has been awarded a $216 million Federal Supply Schedule (FSS) contract by the Department of Veterans Affairs (VA) for pharmaceuticals and drugs under the Pharmaceuticals and Drugs (FSS-61-IB) schedule. This multiple-award, unrestricted IDV contract enables Hikma to deliver a wide range of pharmaceutical products, including injectable solutions, tablets, and specialized medications, to military treatment facilities, VA healthcare networks, and other government healthcare systems.
Additionally, Hikma holds a $38.5 million single-award Blanket Purchase Agreement (BPA) with the VA's National Acquisition Center for the procurement of the controlled substance sodium oxybate, as well as a $42.9 million single-award Indefinite Delivery Contract with the Defense Logistics Agency (DLA) Troop Support Medical. These IDVs further position Hikma as a critical supplier of pharmaceutical products, including naloxone, doxycycline, ketamine, and benztropine, to both defense and civilian federal agencies. None of Hikma's federal contract awards include set-aside designations, reflecting the company's status as a large, capable pharmaceutical manufacturer able to meet complex government procurement requirements.
Generated 3/7/25, 10:07 AM